Citation Impact
Citing Papers
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
2014 Standout
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
2011 Standout
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Hierarchical design of pseudosymmetric protein nanocages
2024 StandoutNatureNobel
A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model
2007 StandoutNobel
HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas
2006
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Dendritic cells in cancer immunology and immunotherapy
2019 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Recombinant Human Erythropoietins and Cancer Patients: Updated Meta-Analysis of 57 Studies Including 9353 Patients
2006
Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia
2008
Anticoagulation for patients with cancer and central venous catheters
2011
Personalized treatment of early-stage breast cancer: Present concepts and future directions
2010
Targeted therapies in breast cancer: are heart and vessels also being targeted?
2012
Breast cancer
2016 Standout
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
Role of Gemcitabine in Breast Cancer Management: An Update
2006
Management of occlusion and thrombosis associated with long-term indwelling central venous catheters
2009
Antithrombotic Therapy for VTE Disease
2016 Standout
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
2011 Standout
Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis
2012
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice
2005 Standout
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Definition and classification of cancer cachexia: an international consensus
2011 Standout
Prevention of VTE in Nonsurgical Patients
2012 Standout
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis
2004
Peptide-based materials for cancer immunotherapy
2019
Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study
2008 Standout
Cancer genes and the pathways they control
2004 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Anticoagulation for patients with cancer and central venous catheters
2011
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Self-assembling protein nanoparticles in the design of vaccines
2015
The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
2010 Standout
mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model
2022 StandoutNobel
Prevention of Venous Thromboembolism
2004 Standout
Genomic instability — the engine of tumorigenesis?
2003
Analysis of anticancer drugs: A review
2011 Standout
Novel targets in gastric and esophageal cancer
2006
Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients
2008
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Prevention of Venous Thromboembolism
2008 Standout
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules
2009
Phase II Trial of Gemcitabine plus Trastuzumab in Metastatic Breast Cancer Patients Previously Treated with Chemotherapy: Preliminary Results
2002
Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis
2015 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Risk factors for catheter‐related thrombosis (CRT) in cancer patients: a patient‐level data (IPD) meta‐analysis of clinical trials and prospective studies
2010
Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters
2007
Guidelines for the Prevention of Intravascular Catheter-related Infections
2011 Standout
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
Role of the Glutathione Metabolic Pathway in Lung Cancer Treatment and Prognosis: A Review
2006
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
2017 Standout
Symptom Assessment in Palliative Care: A Need for International Collaboration
2008
Interventions for preventing neuropathy caused by cisplatin and related compounds
2014
Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer
2014
Nanoparticle albumin-bound (nab™)-paclitaxel: improving efficacy and tolerability by targeted drug delivery in metastatic breast cancer
2010
Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation
2011
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America
2017 Standout
Breast Cancer Treatment
2019 Standout
Improved determination of 5‐fluorouracil and its prodrug tegafur in pharmaceuticals by large‐volume sample stacking in CE
2007
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
2014 Standout
Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials
2010
Long-Term Toxicity Monitoring via Electronic Patient-Reported Outcomes in Patients Receiving Chemotherapy
2007
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Development and validation of a predictive model for chemotherapy-associated thrombosis
2008 Standout
A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposes.
2010
Medical Management of Brain Metastases and Leptomeningeal Disease in Patients with Breast Carcinoma
2018
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Nanoparticles: Augmenting Tumor Antigen Presentation for Vaccine and Immunotherapy Treatments of Cancer
2017
Management of people with early- or very early-stage hepatocellular carcinoma
2017
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
2015 Standout
Patient Online Self-Reporting of Toxicity Symptoms During Chemotherapy
2005
Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial
2011
Works of G. Steger being referenced
Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer.
2000
Penetration of capecitabine and its metabolites into malignant and healthy tissues of patients with advanced breast cancer
2003
Genetic analysis of multiple synchronous lesions of the colon adenoma–carcinoma sequence
2000
Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment
2003
A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study
2009
Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
2011
Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy.
2003
Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial
2005
Decrease of duration and symptoms in chemotherapy-induced oral mucositis by topical GM-CSF
2001
The clinical course of lung metastases from breast cancer
1988
Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study
2003
Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer
2000
Neoadjuvant Chemotherapy in Liver Transplantation for HCC: Fifteen-Year Outcome of a RCT.
2014
Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.
2008
Feasibility of docetaxel, epirubicin, and capecitabine (TEX) plus pegfilgrastim as neoadjuvant treatment for primary breast cancer: A pilot stud
2004
Final Overall Survival (OS) Results from the Randomised, Double-Blind, Placebo-Controlled, Phase III AVADO Study of Bevacizumab (BV) Plus Docetaxel (D) Compared with Placebo (PL) Plus D for the First-Line Treatment of Locally Recurrent (LR) or Metastatic Breast Cancer (mBC).
2009
Pathologic complete response (pCR) in patient subgroups: An analysis of ABCSG-24, a phase III, randomized study of anthracycline- and taxane-based neoadjuvant therapy with or without capecitabine in early breast cancer (EBC).
2010